W STRATEGIES, LLC for ABBVIE INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
FY 2017 MILCON/VA appropriations as it relates to increased appropriations for Viral Hepatitis Testing for VA. S. 524: Comprehensive Addiction and Recovery Act of 2016 as it relates to Rx take back programs. Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars. H.R. 6: 21st Century Cures Act. Education about the value of innovative new medicines. Education about the 340(b) program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Medicare/Medicaid MMM
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program. March 2016 CMS proposed rule implementing a new Part B drug payment model.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.